abatacept

Ligand id: 6891

Name: abatacept

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: abatacept

References
1. Davis IC, Randell J, Davis SN. (2015)
Immunotherapies currently in development for the treatment of type 1 diabetes.
Expert Opin Investig Drugs24 (10): 1331-41. [PMID:26364507]
2. Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B et al.. (2017)
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
J. Immunol.198 (1): 528-537. [PMID:27881707]
3. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. (1991)
CTLA-4 is a second receptor for the B cell activation antigen B7.
J. Exp. Med.174 (3): 561-9. [PMID:1714933]
4. Ludvigsson J. (2016)
Therapies to Preserve ╬▓-Cell Function in Type 1 Diabetes.
Drugs76 (2): 169-85. [PMID:26645223]
5. Vicente Rabaneda EF, Herrero-Beaumont G, Casta├▒eda S. (2013)
Update on the use of abatacept for the treatment of rheumatoid arthritis.
Expert Rev Clin Immunol9 (7): 599-621. [PMID:23899231]